Abstract
Magnetic dynamics studies by AC susceptibility technique have been performed on the two newest-generation iron deficiency drugs, commercialized under the trade names Feraheme and Monofer. In all aspects, these magnetic nanoparticle systems obey a common pattern of superparamagnetism characterized by similar blocking temperatures, average particle sizes, and magnetocrystalline anisotropy energy. However, effective magnetic moments associated with average particle of each drug are remarkably different, being approximately 10630 μB (Feraheme) and 134 μB (Monofer). The difference relies on qualitatively different magnetic interaction permeating the iron cores of the constituent nanoparticles. The nanoparticle of each system can be classified as monodomain ferrimagnet (Feraheme) and almost compensated antiferromagnet (Monofer). In accordance with different associated moments the dipole-dipole interaction between nanoparticles for the two drugs differs for orders of magnitudes but remains safely small at room temperatures. For reference, the corresponding measurements on previously better investigated iron-sucrose haematinic Venofer has been also performed and included in this article.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
